The medical device maker reported adjusted EPS of $0.86 on $5.442 billion revenue, exceeding expectations and raising its full-year outlook.
Boston Scientific Corp posted second-quarter adjusted earnings per share of $0.86, beating the $0.83 consensus, as revenue climbed to $5.442 billion from $5.37 billion expected. The company raised its full-year sales forecast following the results.
Revenue grew 7.5% year-over-year on a reported basis, with the Cardiovascular segment leading at 8.3% growth. Adjusted EPS rose from $0.75 in the prior-year quarter, while GAAP net income increased to $907 million from $797 million.
The company cited disciplined execution and strategic investments as key drivers, reinforcing confidence in long-term growth amid a dynamic operating environment.